US: 1.917.963.8646 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Global Bacterial Antigens Market 2021: By Antigen Type (Chlamydia trachomatis, Native Chlamydia trachomatis, Clostridium difficile Toxoid A, Clostridium difficile Toxoid B, Native Lipoteichoic Acid, Neisseria gonorrhoeae, Recombinant Protein G, Trichomonas vaginalis), By Diagnostic Techniques (ELISA, Immunoassay, SDS-PAGE, Hemagglutination, Agglutination test, Other Diagnostic Techniques), By End User (Diagnostic Laboratories and Centers, Academic and Research Institutes, Hospital)Global Bacterial Antigens Market is the title of an upcoming report being generated at Trusted Business Insights. The report is streamlined to provide crucial insights and information into details of revenues, investments, R&D, sales, leaders in the market on the basis of manufacturers in the target market etc. The report comprises other information, such as the various trends, drivers, restraints, opportunities, and threats, along with historical and projected revenues. The top players section in the company profile section of the report contain a range of information and details related to the company, along with respective revenues, technological innovations and advancements, recent and key developments, strategies, acquisitions and mergers, and market footprint. The global bacterial antigens market is segmented on the basis of industrial vertical, applicable system, protection method, and regions and countries.
Overview:Antigen is a substance capable of triggering an immune response in a host body by activating lymphocytes against the infection. The antigens that are produced inside the body are called self-antigens, and those induced from an external environment are called foreign antigens. Self-antigens are types of overexpressed proteins. Foreign antigens include parasites, bacteria, chemicals, viruses, and some toxins and proteins, which are found in food products. B Cells of the human body identifies the bacterial antigens and produces a stronger immune response.
DynamicsBacterial antigens are used to develop various types of antibodies in research laboratories to improve the immune system. Bacterial antigens are found in the different form such as inactivated, purified, conjugates, etc. Native state bacterial antigen is high in demand mainly for vitro diagnostics & vaccine research. There are various standard properties of bacterial antigen such as higher sensitivity, higher specificity, minimal lot-to-lot variation, extended shelf-life, etc. Bacterial antigens can be used in various diagnostic techniques such as ELISA, Immunoassay, SDS-PAGE, Agglutination test, etc. Some of the potential and major end users of bacterial antigens are academic and research institutes, diagnostic laboratories, and centers. Drivers: Rapidly growing incidences of bacterial infectious diseases such as Tuberculosis, Syphili, Leptospirosis, rheumatic fever, etc. globally is projected to drive growth of the global bacterial antigens market in the foreseeable future. Restraints: Stringent government rules and regulations have been implemented and companies need to comply with these to secure approval for new bacterial antigens, which can act as a restraining factor for growth of the global bacterial antigens market. Opportunities: An increasing number of new bacterial infections and other types of diseases can create new opportunities for major in the market. Trends: The global trend of discovery of novel antigens that can trigger a cross-protective immune response is affecting the global bacterial antigens market positively.
Market Segmentation:By Antigen Type: Among the antigen type segments, the clostridium difficile toxoid A segment is projected to account for majority revenue share in the global market, owing to wide usage in treating various diseases such as gastritis. By Diagnostic Techniques: Among the diagnostic techniques segments, the immunoassay segment currently accounts for majority revenue share in the global bacterial antigens market, and the trend is expected to continue over the forecast period. By End User: Among the end user segments, the diagnostic laboratories and centers segment currently accounts for majority revenue share and is projected to account for majority revenue share in the bacterial antigens market due to increasing government funding towards development of diagnostic laboratories and centers.
Regional Analysis:The region-wise segmentation includes North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The North America bacterial antigens market is expected to account for a significantly high revenue share in the near future due to increasing research activities related to bacterial antigens. After North America, the Asia Pacific bacterial antigens market is projected to register higher CAGR owing to presence of large number of end users in countries in the region. Revenue from the Europe bacterial antigens market is expected to grow at slow rate post-recovery from the global lockdown of almost all industries and sectors during the Coronavirus of COVID-19 pandemic in countries in the region. The Europe market however, is projected to regain some stability towards the first two years at the initial phase of the forecast period.
Below are the active patents related to Bacterial Antigens Market.Patent Number: US7790386B2 Neisseria gonorrhoeae specific oligonucleotide sequences Abstract The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the selective and specific detection of Neisseria gonorrhoeae in biological samples. The invention also provides oligonucleotide primer sets and primer/probe sets in the form of kits for the detection and diagnosis of gonococcal infection. The inventive oligonucleotide primers and probes can also be used in combination with other specific oligonucleotide primers and probe for the simultaneous detection of Neisseria gonorrhoeae and other target organisms, such as Chlamydia trachomatis. Type: Grant Filed: 2007-04-06 Date of Patent: 2010-09-07 Assignee : Siemens Healthcare Diagnostics Inc Patent Number: US7357932B2 Surface protein of Neisseria bacteria Abstract Present invention provides a monoclonal antibody binding to Neisseria bacteria and its target antigen Ag473, which include the sequences of its polynucleotide and its amino acid, wherein the Neisseria bacteria can be Neisseria meningitidis or Neisseria gonorrhoeae; and wherein Ag473 can be made into a vaccine or a diagnostic or therapeutic reagent. Type: Grant Filed: 2004-06-16 Date of Patent: 2008-04-15 Assignee : CENTER FOR DISEASE CONTROL DEPARTMENT OF HEALTH TAIWAN ROC, Center for Disease Control
Below are the leading companies profiled in this Bacterial Antigens Market Report:
Chapter 1 Methodology and Scope